Children addiction treatment and rehabilitation residential centers in Iran: report of a pilot study-Reference-Cited by-同舟云学术

Children addiction treatment and rehabilitation residential centers in Iran: report of a pilot study

Published:2019-10-16 Issue:2 Volume:25 Page:201-204
ISSN:1465-9891
Container-title:Journal of Substance Use
language:en
Short-container-title:Journal of Substance Use

Author:

Roshanpajouh Mohsen¹,Mirkazemi Roksana²,Maleki Moghaddam Mahdieh³,Saravani Mohammad⁴,Rahat Dahmardeh Maasoumeh⁴,Asadi Hassan⁴,Rezazadeh Majid⁵

Affiliation:

1. Addiction Department, School of Behavioral Sciences and Mental Health (Tehran Psychiatry Institute), Iran University of Medical Sciences, Tehran, Iran

2. Farzanegan Nik Andish Institute for the Development of Knowledge and Technology, Tehran, Iran

3. Office of Children Program, Headquarters Welfare Organization of Sistan and Balouchestan Province, Zahedan, Iran

4. Department of Addiction Prevention, Welfare Organization of Sistan and Balouchestan Province, Zahedan, Iran

5. Deputy of Development of Prevention, State Welfare Organization (SWO), Tehran, Iran

Publisher

Informa UK Limited

Subject

Health (social science),Medicine (miscellaneous)

Link

https://www.tandfonline.com/doi/pdf/10.1080/14659891.2019.1675785

Reference20 articles.

1. Child and adolescent mental disorders: the magnitude of the problem across the globe

2. More than just someone to inject drugs with: Injecting within primary injection partnerships

3. Rehabilitation from substance abuse in individuals with a history of sexual abuse

4. Preventing Adolescent Drug Abuse and High School Dropout through an Intensive School-Based Social Network Development Program

5. The Journey of Addiction: Barriers to and Facilitators of Drug Use Cessation among Street Children and Youths in Western Kenya

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Public health risks associated with methadone in Iran: A systematic review and meta-analysis;International Journal of Drug Policy;2022-02